Navigation Links
Famed IT Investor and Director of 23andme Esther Dyson Identifies on IdeasProject.com Genetic Information as an Extremely Disruptive Force
Date:2/12/2009

Video interview with Dyson featured on IdeasProject.com, Nokia's new website, which provides innovative ways to interact with thought leaders and their "big ideas" about the future of communications

San Francisco, CA (PRWEB) February 12, 2009 -- Esther Dyson, IT investor, catalyst to numerous start-ups, and director of genetic testing service 23andme, says that as we further our understanding of genetics, scientists in turn will be enabled to reconfigure how genes work to achieve desired results. Dyson foresees future technology where scientists will be able to inject a specific genomic structure into an individual to save their life, or through proper genomic identification, identify the appropriate drug to treat their ailment.

A video interview with Dyson talking about genetic information being disruptive is featured on IdeasProject, a unique website developed by Nokia. IdeasProject is an online space that provides a new way to interact with thought leaders and their big ideas about the future of connected communications. For more on Dyson's idea, visit http://www.ideasproject.com/idea_person.webui?id=1111

"The more people know, the more conscious they are of how things work, and the more likely they are to make better decisions," said Dyson. "One area in which people's decisions have a huge impact is their own personal health and understanding of how that works. The impact of their behavior is going to make more people make better decisions of their own volition without being forced or deluded into doing things they don't want to do."

"We are proud to feature such luminaries as Esther Dyson in the IdeasProject," says Valerie Buckingham, director of technology marketing, Nokia. "In the same way that Esther h
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2 3

Related biology technology :

1. BioMed Realty Trust Announces New Financing for Joint Venture With Prudential Real Estate Investors
2. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
3. Transcept Pharmaceuticals to Present at 11th Annual BIO CEO & Investor Conference
4. In Analyst Interview, Cord Blood America Says Stem Cells Now Front and Center for Researchers and Investors
5. BioMS Medical to present at BIO CEO and Investor Conference
6. Micromet to Present at the BIO CEO and Investor Conference on February 10, 2009
7. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
8. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
9. Sunesis to Present at the 11th Annual BIO CEO & Investor Conference
10. Monsanto Executives to Discuss Companys Growth Drivers, Profit Goals at Investor Conferences in February
11. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Famed IT Investor and Director of 23andme Esther Dyson Identifies on IdeasProject.com Genetic Information as an Extremely Disruptive Force
(Date:7/30/2015)... ... , ... The 2015 Market Research Report on the Global Propanol Industry ... Propanol market with a focus on the Chinese situation. Major companies included in the ... Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. , The report ...
(Date:7/30/2015)... ... July 30, 2015 , ... Leading regenerative ... study of its canine osteoarthritis stem cell product, currently under development for FDA ... and will be marketed in the US by Aratana. This product, termed AT-016, ...
(Date:7/30/2015)... July 30, 2015   Senomyx , Inc. (NASDAQ: ... science technologies to discover, develop, and commercialize novel flavor ... today reported financial results for the second quarter 2015. ... 2015, we remain on track to achieve our commercial ... Executive Officer of the Company. "Since our last quarterly ...
(Date:7/30/2015)... COPENHAGEN, Denmark , July 30, 2015 /PRNewswire/ ... a biotechnology company that applies its innovative TransCon ... announced positive top-line results from a six-month Phase ... of once-weekly TransCon Growth Hormone in 53 treatment-naïve, ... "We are extremely pleased with the ...
Breaking Biology Technology:Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... 23 BioElectronics,Corporation, (Pink Sheets: BIEL), announced ... signed an agreement for the distribution of,ActiPatch(TM) ... October 10th. TSS Medical joins the ... BioElectronics has signed agreements in place and,shipping ...
... Scientific ... ... 23 /PRNewswire-FirstCall/,-- TopSpin Medical (TASE: TOPMD) announced today that the ... Resonance Imaging System During Coronary Endovascular,Catheterization (TOPIMAGE) demonstrated the safety ...
... 22 /PRNewswire-FirstCall/ - YM BioSciences Inc.,(AMEX: YMI ... that identifies,develops and commercializes differentiated products for patients ... adopted a renewed,Shareholder Rights Plan Agreement. The Rights ... shareholders in connection with any take-over offer,for the ...
Cached Biology Technology:BioElectronics Corporation Announces Distribution Agreement With TSS Medical of Italy 2Clinical Study Findings Show Safety and Procedure Success for TopSpin IntraVascular MRI Catheter for the Coronary Arteries 2Clinical Study Findings Show Safety and Procedure Success for TopSpin IntraVascular MRI Catheter for the Coronary Arteries 3YM Biosciences announces adoption of renewed Shareholders' Rights Plan 2YM Biosciences announces adoption of renewed Shareholders' Rights Plan 3
(Date:7/23/2015)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its second quarter ended June 30, 2015.  ... a decrease of 33% compared to $6.8 million in the ... of 2015 was $0.3 million, or $0.01 per diluted share, ... in the same period a year ago.  ...
(Date:7/21/2015)... Connecticut , July 21, 2015  NXT-ID, ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet, announces that it has filed ... System and Method. This invention ... not only authorizes an account, but also the ...
(Date:7/13/2015)... Calif. , July 13, 2015 ... developer of human interface solutions, today announced sampling ... touch and display driver integration (TDDI) product targeting ... the first to combine Synaptics , best-in-class ... proven display driver technology developed in the company,s ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
... Researchers with the International Agency for Research on Cancer ... significantly more likely to have several high-risk forms of ... not have lung cancer. These results, which were presented ... 2-6, indicate that HPV antibodies are substantially increased in ...
... In the largest study of its kind, researchers from ... new genes linked to late-onset Alzheimer,s disease. Each of these ... form of the disease, and together they offer a portal ... find ways to determine who is at risk of developing ...
... long been associated with religious rituals, diets, and political ... Intermountain Medical Center Heart Institute demonstrates that routine periodic ... heart. Today, research cardiologists at the Intermountain Medical ... lowers one,s risk of coronary artery disease and diabetes, ...
Cached Biology News:Lung cancer risk rises in the presence of HPV antibodies 2Alzheimer’s disease consortium identifies four new genes for Alzheimer’s disease risk 2Alzheimer’s disease consortium identifies four new genes for Alzheimer’s disease risk 3Study finds routine periodic fasting is good for your health, and your heart 2Study finds routine periodic fasting is good for your health, and your heart 3
Dnase and Rnase free...
TLN2 Antibody...
Mouse monoclonal [0.N.305] to G protein alpha - BSA and Azide free ( Abpromise for all tested applications). Antigen: Partially purified G protein alpha from rat brain. Entrez GeneID: 2778 ...
Rabbit polyclonal to VEGF Receptor 2 (phospho Y1214) ( Abpromise for all tested applications). entrezGeneID: 3791 SwissProtID: P35968...
Biology Products: